Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 10200261.
- Also identified by PMC identifier 16331.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent studies identified a short peptide motif that serves as a docking site for cyclin/cyclin-dependent kinase (cdk) 2 complexes. Peptides containing this motif block the phosphorylation of substrates by cyclin A/cdk2 or cyclin E/cdk2. Here we report that cell membrane-permeable forms of such peptides preferentially induced transformed cells to undergo apoptosis relative to nontransformed cells. Deregulation of E2F family transcription factors is a common event during transformation and was sufficient to sensitize cells to the cyclin/cdk2 inhibitory peptides. These results suggest that deregulation of E2F and inhibition of cdk2 are synthetically lethal and provide a rationale for the development of cdk2 antagonists as antineoplastic agents.
Medical subject headings
- Antineoplastic Agents
- CDC2-CDC28 Kinases
- Carrier Proteins
- Cell Cycle Proteins
- Cyclin-Dependent Kinases
- Cyclins
- DNA-Binding Proteins
- Enzyme Inhibitors
- Peptides
- Protein Serine-Threonine Kinases
- Transcription Factors